Repligen Stock News

The European Commission approves Vertex's (VRTX) triple combination therapy, Kaftrio, in combination with Kalydeco for treating cystic fibrosis in children aged between six and 11 years.

Repligen (RGEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising

Repligen (RGEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising

Repligen Corp. (RGEN) shares closed this week 21.9% lower than it did at the end of last week. The stock is currently down 21.9% year-to-date, down 0.8% over the past 12 months, and up 524.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Shares traded as high as $265.78 and as low as $204.10 this week.Shares closed 36.8% below its 52-week high and 27.4% above its 52-week low.Trading volume this week was 13.1% higher than the 10-day average and 57.8% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 190.2% The company's stock price performance over the past 12 months lags the peer average by -117.5% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 12.0% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Commodities were the only major index to gain ground last week. Read here for a detailed review...

Acadia Healthcare (ACHC) is poised for growth due to higher revenues driven by solid demand for behavioral health services, multiple JVs with established healthcare systems and debt repayment efforts.

J&J (JNJ) submits a Biologics License Application, seeking approval for its bispecific antibody candidate teclistamab as a treatment option for the heavily pretreated multiple myeloma patients.

WALTHAM, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present vir

WALTHAM, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtu

Smart Beta ETF report for RFG

Pluristem's (PSTI) phase II studies evaluating PLX-PAD cells for treating acute respiratory distress syndrome associated with COVID-19 fail to achieve the primary endpoint.

Goldman Sachs, GameStop, Repligen, Sarepta Therapeutics and BeiGene highlighted as Zacks Bull and Bear of the Day

Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.

ChemoCentryx's (CCXI) Tavneos gives a significant boost to the company, following its FDA approval in ANCA-associated vasculitis. The drug is also being evaluated in other indications.

Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.